clinical trial · NCT06874010
A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia
Friedreich AtaxiaDT-216P2
brief summary
The purpose of this study is to evaluate the safety and tolerability, and pharmacokinetics of DT-216P2 administered multiple ascending doses in patients with FA.
started
Jun 1, 2025
primary completion
Dec 1, 2026
completion
Mar 1, 2027
last updated
May 18, 2025
official title
A Phase 1/2, Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intravenous DT-216P2 in Patients With Friedreich's Ataxia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol